Press-release for stocks for johnson & johnson

for entities : Johnson & johnson

save search

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Published: 2024-04-22 (Crawled : 18:00) - biospace.com/
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| 0.82% | O: 0.29% H: 0.0% C: 0.0%
LEGN | News | $46.36 -1.49% 270K

Health Technology

| 1.88% | O: 0.39% H: 1.73% C: 1.49%
carvykti approved treatment for

Innovative Aspiration Thrombectomy System by Expanse ICE Receives FDA Clearance for vessels of the peripheral arterial and venous systems
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| 0.82% | O: 0.29% H: 0.0% C: 0.0%
fda clearance system for ice

Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Crawled : 15:00) - biospace.com/
PRGO | $30.45 1.3% 230K

Health Technology

| 0.07% | O: -0.4% H: 3.01% C: 2.94%
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| 2.88% | O: 0.83% H: 1.35% C: 1.2%
ABT | News | $108.01 0.88% 1.2M

Health Technology

| 0.63% | O: -0.75% H: 0.0% C: 0.0%
SNY | News | $47.5 0.74% 450K

Health Technology

| 1.68% | O: 0.82% H: 0.0% C: 0.0%
first treatment for

FDA Requires Boxed Warning for Secondary Cancers on CAR-T Therapies
Published: 2024-04-19 (Crawled : 12:00) - biospace.com/
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| 2.88% | O: 0.83% H: 1.35% C: 1.2%
fda for car-t

Teva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 Launch
Published: 2024-04-18 (Crawled : 14:00) - biospace.com/
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| 3.0% | O: 0.12% H: 0.0% C: 0.0%
fda biosimilar approval for stelara

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
GNMSF | News | $289.67 5.3K

Health Technology

| 2.72% | O: 4.94% H: 0.0% C: -3.66%
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| 0.65% | O: -2.09% H: 0.0% C: 0.0%
GMAB | News | $28.885 -0.29% 190K

Health Technology

| -1.6% | O: -1.29% H: 1.91% C: 1.27%
darzalex sales first for

Robbins Geller Rudman & Dowd LLP, Lieff Cabraser Heimann & Bernstein LLP, and Dugan Law Firm, APLC Announce a $78 Million Class Action Settlement for Third Party Payors That Paid or Reimbursed Costs for Prescription Opioids or Treatment Related to Opioid Misuse, Addiction, and/or Overdose
Published: 2024-04-15 (Crawled : 20:00) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| 0.65% | O: -2.09% H: 0.0% C: 0.0%
opioid million treatment for

AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-15 (Crawled : 12:00) - biospace.com/
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| 0.61% | O: -0.04% H: 0.0% C: 0.0%
avb-101 first dementia for trial

AstraZeneca Wins Label Expansion for Severe Asthma Drug in Younger Kids
Published: 2024-04-12 (Crawled : 14:30) - biospace.com/
PRGO | $30.45 1.3% 230K

Health Technology

| -3.9% | O: -0.13% H: 0.0% C: -2.94%
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| -1.05% | O: -1.65% H: 0.0% C: 0.0%
ABT | News | $108.01 0.88% 1.2M

Health Technology

| -3.93% | O: -1.06% H: 0.21% C: -1.05%
SNY | News | $47.5 0.74% 450K

Health Technology

| -2.38% | O: -3.02% H: 0.0% C: 0.0%
drug label astrazeneca expansion for kids

Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year
Published: 2024-04-12 (Crawled : 13:00) - globenewswire.com
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| -1.05% | O: -1.65% H: 0.0% C: 0.0%
expected year revenue for financial

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
RLYB | News | $1.85 4.52% 89K

| 7.27% | O: -3.03% H: 4.38% C: 1.87%
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| -1.47% | O: 0.21% H: 0.0% C: 0.0%
risk solutions for collaboration

Busy Weekend Sees Tumor-Agnostic Win for Enhertu, Another Rejection for Supernus
Published: 2024-04-08 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 600K

Health Technology

| 0.01% | O: 2.24% H: 0.0% C: -0.8%
PRGO | $30.45 1.3% 230K

Health Technology

| -4.27% | O: 0.96% H: 1.17% C: 0.16%
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| -2.24% | O: -0.48% H: 0.0% C: 0.0%
ABT | News | $108.01 0.88% 1.2M

Health Technology

| -3.71% | O: 0.09% H: 0.16% C: -0.7%
SNY | News | $47.5 0.74% 450K

Health Technology

| -1.39% | O: 0.84% H: 0.0% C: 0.0%
for

FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment
Published: 2024-04-06 (Crawled : 16:20) - biospace.com/
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| Email alert Add to watchlist
fda treatment for car-t

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Published: 2024-04-06 (Crawled : 04:20) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| Email alert Add to watchlist
carvykti fda first approved one treatment for therapy

FDA Greenlights New Antibiotic for SAB, Pneumonia
Published: 2024-04-05 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 600K

Health Technology

| -3.54% | O: -1.77% H: 0.0% C: -1.81%
PRGO | $30.45 1.3% 230K

Health Technology

| -4.42% | O: -0.22% H: 0.8% C: 0.06%
JNJ | News | $149.575 0.31% 2.5M

Health Technology

| -4.04% | O: -1.84% H: 0.0% C: 0.0%
ABT | News | $108.01 0.88% 1.2M

Health Technology

| -2.76% | O: -0.37% H: 1.42% C: 1.37%
SNY | News | $47.5 0.74% 450K

Health Technology

| -4.77% | O: -3.44% H: 0.0% C: 0.0%
fda for

Basilea Wins FDA Approval for Antibiotic Ending 15-Year Regulatory Quest
Published: 2024-04-04 (Crawled : 15:00) - biospace.com/
JNJ | News | $149.575 0.31% 2.5M

Health Technology